<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26552">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01659515</url>
  </required_header>
  <id_info>
    <org_study_id>S-11-0001</org_study_id>
    <nct_id>NCT01659515</nct_id>
  </id_info>
  <brief_title>Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria</brief_title>
  <official_title>Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Meiji Seika Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uniformed Services University of the Health Sciences</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this protocol is to make arbekacin available for treatment of
      patients with infections caused by multidrug-resistant organisms when treatment with other
      antibiotics cannot be used due to unavailability, intolerance, contraindications, or
      treatment non-response.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <study_design>N/A</study_design>
  <condition>Infection Due to Resistant Organism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arbekacin Sulfate</intervention_name>
    <description>Intravenous arbekacin in a total daily dose of 5-7 mg/kg</description>
    <other_name>Arbekacin</other_name>
    <other_name>Habekacin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is military health care beneficiary at least 18 years of age;

          2. Subject is a Walter Reed National Military Medical Center patient deemed by the
             primary medical or surgical team as having a bacterial infection of the respiratory
             tract, bloodstream, skin, soft tissue, bone, or genitourinary tract;

          3. Subject is allergic to or intolerant of antibiotics to which the infective organism
             is susceptible; Or The use of antibiotics to which the subject's infective organism
             is susceptible is contraindicated; Or

             Subject's infective organism isolate is a multidrug-resistant (MDR) bacterium defined
             as any of the following:

               -  Gram-negative bacterium that is non-susceptible to all index antibiotics within
                  3 or more of 6 antibiotic classes including aminoglycosides (amikacin,
                  gentamicin, tobramycin), beta-lactam/beta-lactam inhibitor combinations
                  (piperacillin-tazobactam, amoxicillin-clavulanate), carbapenems (imipenem,
                  ertapenem), fluoroquinolones (ciprofloxacin, levofloxacin), cephalosporins
                  (ceftazidime, cefepime, ceftriaxone), and sulbactam (ampicillin-sulbactam);

               -  Extended Spectrum β-lactamase (ESBL) producing Gram-negative bacterium;

               -  Carbapenemase resistant Enterobacteriaceae;

               -  Cephalosporin resistant Klebsiella species;

               -  Methicillin-resistant Staphylococcus aureus (MRSA);

               -  Vancomycin resistant Enterococcus species;

               -  Staphylococcus aureus that is non-susceptible to vancomycin.

          4. Subject's infective organism is inhibited in vitro by arbekacin at a concentration ≤
             4 μg/mL;

          5. Subject is able to give written or witnessed verbal informed consent [An exception
             from the general requirements for informed consent can be made based upon the
             criteria specified in 21 Code of Federal Regulations 50.23 (a and c)];

          6. Subject has adequate venous access for intravenous administration of arbekacin.

        Exclusion Criteria:

          1. Subject has a history of allergy or serious adverse reaction to aminoglycoside
             antibiotics;

          2. Subject is currently participating in another investigational new drug study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Michael Zapor, MD, PhD</last_name>
    <phone>301-677-8124</phone>
    <email>Michael.j.zapor.mil@mail.mil</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christa M Madock</last_name>
    <phone>(301) 619-4649</phone>
    <email>christa.madock@us.army.mil</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center (WRNMMC)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Zapor, MD, PhD</last_name>
      <phone>301-677-8124</phone>
      <email>Michael.j.zapor.mil@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Michael Zapor, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>August 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Habekacin</mesh_term>
    <mesh_term>Dibekacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
